TX-FLUENCE
19.10.2021 15:02:06 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it will debut products at MJBizCon 2021, including its high-output SPYDR 2h, SPYDR Fang, waterproof RAZR Enclosed and next-generation RAPTR top light as well as its new lighting controls, Wireless Flex Dimming and the SHYFT Light Scheduler.
Following the announcement of its multiyear global research study results —which showcased the effects of broad-spectrum lighting solutions on crop yield and quality—Fluence will demo its innovative new products at the company’s MJBizCon booth, located at No. C3515.
“In our recently announced research results, Fluence noted a clear, positive impact on cannabis crop yield, cannabinoid content and overall plant quality under broad-spectrum lighting,” said David Cohen, CEO of Fluence. “According to the 2021 State of the Cannabis Lighting Market report , LED usage for cannabis cultivation has increased more than 45 percent for all stages of growth since the initial report in 2016. The efficacy of LED lighting solutions for cannabis cultivation is no longer a question. Cultivators have embraced the power of LEDs and are seeking new ways to harness broad-spectrum lighting technology to optimize their cultivation environments. Fluence’s innovative new products—informed by the latest photobiology research—will enable cultivators to achieve exceptional crop performance.”
The latest luminaires from Fluence include:
- SPYDR 2h: An extension of Fluence’s SPYDR series—featuring luminaires designed for single- or multitier growers who want to optimize grow space—the company’s high-output SPYDR 2h produces a photosynthetic photon flux of up to 2,080 μmol/s. Supported by results from Fluence’s multiyear global research studies observing cannabis growth under high light intensities, the SPYDR 2h is designed to maximize yields.
- SPYDR Fang: The SPYDR Fang is designed specifically for the retail buyer and built with Fluence’s trusted, research-backed and science-led engineering leveraged by commercial growers throughout the world.
- RAZR Enclosed: Following its debut in June 2021, the RAZR Modular System is now IP67 waterproof to withstand hyper-wet and humid environments within a vertical farm. The RAZR series is also now available with various spectral options, including broad-white as well as dual red and blue light. Fluence will showcase the system’s newest features through video at the company’s MJBizCon booth.
- RAPTR: Fluence’s latest top light solution serves as an advanced one-to-one high-pressure sodium replacement. The next-generation top light consumes 1,000 watts at a high output, plugging in seamlessly to a grower’s existing facility for streamlined retrofits.
“Fluence’s high-output SPYDR 2h will transform how cannabis cultivators approach each stage of plant production,” said Jordon Musser, chief product officer for Fluence. “We’ve seen incredible yield and quality metrics at high PPFDs and we’re excited to collaborate with our growers to incorporate high-intensity lighting and cultivation strategies into their operations.”
The company will also debut its innovative lighting controls, including:
- SHYFT: Available in North America, Fluence’s light scheduler, SHYFT, offers patented photoacclimation capability and daily photoperiod control for 0 to 10 V LED and dimmable fluorescent fixtures. At MJBizCon, visit the Fluence booth to see SHYFT control each of the company’s luminaires and witness its advanced lighting control capabilities.
- Wireless Flex Dimming: In addition to SHYFT, Fluence’s Wireless Flex Dimming solution leverages Bluetooth mesh technology to wirelessly control fixtures. With Wireless Flex Dimming’s plug-and-play design, growers gain increased flexibility over light levels with no wire installations or additional labor costs. Fluence team members will demo the product’s wireless capabilities from within the booth.
“MJBizCon is the world’s stage for unveiling leading cannabis innovations and we’re thrilled to debut multiple solutions that are advancing the global cannabis market forward,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re eager to showcase our new products at MJBizCon and exemplify how Fluence is helping cannabis cultivators grow smarter.”
For more information on Fluence, its products and release dates for the company’s newest solutions, visit the team at MJBizCon from Oct. 20, 2021 to Oct. 22, 2021 at booth No. C3515 or explore Fluence’s website at www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom